Entyce (Capromorelin) is a ghrelin receptor agonist that works to increase hunger. It is FDA-approved for use in dogs. Entyce mimics ghrelin (called the “hunger hormone”) in the stomach at the ghrelin receptor, which signals the hypothalamus to increase appetite. Entyce also causes release of growth hormone from the pituitary, which induces the release of insulin-like growth factor (IGF-1). Entyce is metabolized by the liver by CYP3A4 and CYP3A5. Its metabolites are excreted in the urine (37%) and feces (62%).


  • 30mg/ml flavored solution
  • Available in 10, 15, and 30 ml bottles (Ethos currently stocks 10ml and 30ml bottles)


  • Dogs (FDA-approved): 3 mg/kg PO q24 hours. Effectiveness after 4 days has not been evaluated.
  • Cats (off-label): 1-3 mg/kg PO q24 for up to 21 days

Additional resources

  • Capromorelin. Plumb’s Veterinary Drugs.
  • Zollers B, Wofford JA, Heinen E, Huebner M, Rhodes L. A prospective, randomized, masked, placebo-controlled clinical study of capromorelin in dogs with reduced appetite. J Vet Intern Med. 2016;30(6):1851-1857. Download article
  • Wofford JA, Zollers B, Rhodes L, Bell M, Heinen E. Evaluation of the safety of daily administration of capromorelin in cats published online October 22, 2017. J Vet Pharmacol Ther. 2017. doi:10.1111/jvp/12459. Download article
  • Entyce Package Insert. Aratana Therapeutics Inc., Leawood, KS. Download package insert
Last updated: 2018-01-19